公开(公告)号：WO2010006059A8

公开(公告)日：2010-09-02

申请号：PCT/US2009049953

申请日：2009-07-08

Applicant: ABBOTT LAB ,  GU JIJIE ,  HUTCHINS CHARLES W ,  ZHU RONG-RONG ,  SHEN JIANWEI ,  HARRIS MARIA C ,  BELANGER EILEEN ,  MURTAZA ANWAR ,  TARCSA EDIT ,  STINE WILLIAM B ,  HSIEH CHUNG-MING

Inventor： GU JIJIE ,  HUTCHINS CHARLES W ,  ZHU RONG-RONG ,  SHEN JIANWEI ,  HARRIS MARIA C ,  BELANGER EILEEN ,  MURTAZA ANWAR ,  TARCSA EDIT ,  STINE WILLIAM B ,  HSIEH CHUNG-MING

IPC: A61K39/395

CPC classification number: C07K16/18 ,  A61K31/405 ,  A61K31/573 ,  A61K39/39533 ,  A61K2039/505 ,  C07K16/26 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76

Abstract: The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.

Abstract translation: 本发明包括前列腺素E2（PGE2）结合蛋白。 本发明涉及野生型，嵌合，CDR移植和人源化的抗体。 优选的抗体对前列腺素E2具有高亲和力并且在体外和体内中和前列腺素E2的活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗原结合部分可用于检测前列腺素E2和用于抑制前列腺素E2活性，例如，在患有前列腺素E2活性是有害的病症的人类受试者中。

公开(公告)号：CA2728909A1

公开(公告)日：2010-01-14

申请号：CA2728909

申请日：2009-07-08

Applicant: ABBOTT LAB

Inventor： GU JIJIE ,  HUTCHINS CHARLES W ,  ZHU RONG-RONG ,  SHEN JIANWEI ,  HARRIS MARIA C ,  BELANGER EILEEN ,  MURTAZA ANWAR ,  TARCSA EDIT ,  STINE WILLIAM B ,  HSIEH CHUNG-MING

IPC: C07K16/18 ,  A61K39/395 ,  C07K16/46 ,  C12N15/13

Abstract: The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.

公开(公告)号：SG192496A1

公开(公告)日：2013-08-30

申请号：SG2013052923

申请日：2009-07-08

Applicant: ABBOTT LAB

Inventor： GU JIJIE ,  HUTCHINS CHARLES W ,  ZHU RONG-RONG ,  SHEN JIANWEI ,  HARRIS MARIA C ,  BELANGER EILEEN ,  MURTAZA ANWAR ,  TARCSA EDIT ,  STINE WILLIAM B ,  HSIEH CHUNG-MING

Abstract: PROSTAGLANDIN E2 BINDING PROTEINS AND USES THEREOF AbstractThe present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E, activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.Figure I

公开(公告)号：BRPI0915825A2

公开(公告)日：2015-11-03

申请号：BRPI0915825

申请日：2009-07-08

Applicant: ABBOTT LAB

Inventor： MURTAZA ANWAR ,  HUTCHINS CHARLES W ,  HSIEH CHUNG-MING ,  TARCSA EDIT ,  BELANGER EILEEN ,  SHEN JIANWEI ,  GU JIJIE ,  HARRIS MARIA C ,  ZHU RONG-RONG ,  STINE WILLIAM B

IPC: A61K39/395

公开(公告)号：MX2010014573A

公开(公告)日：2011-09-16

申请号：MX2010014573

申请日：2010-12-21

Applicant: ABBOTT LAB

Inventor： HUTCHINS CHARLES W ,  HSIEH CHUNG-MING ,  GU JIJIE ,  ZHU RONG-RONG ,  SHEN JIANWEI ,  HARRIS MARIA C ,  BELANGER EILEEN ,  MURTAZA ANWAR ,  TARCSA EDIT ,  STINE WILLIAM B

IPC: A61K39/395

Abstract: La presente invención abarcar proteínas de unión de prostaglandina E2 (PGE2). La invención se refiere a anticuerpos que son de tipo silvestre, quiméricos, de CDR injertada y humanizados. Los anticuerpos preferidos tienen alta afinidad para prostaglandina E2 y neutralizan la actividad de prostaglandina E2 in vitro e in vivo. Un anticuerpo de la invención puede ser un anticuerpo de longitud completa, o una porción de unión a antígeno del mismo. También se proporcionan métodos para hacer y métodos para utilizar los anticuerpos de la invención. Los anticuerpos, o porciones de unión a antígeno, de la invención son útiles para detectar prostaglandina E2 y para inhibir la actividad de prostaglandina E2, por ejemplo, en un ser humano que sufre de un trastorno en donde la actividad de prostaglandina E2 es dañina.